MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$10,150K
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
8,153
7,987
6,225*
6,437
General and administrative
2,345
2,495
2,612*
2,596
Total operating expenses
-
-
8,836
-
Operating loss
-10,498
-10,482
-8,836*
-9,033
Other income, net
366
447
560
-
Total other income, net
-
-
560*
419
Loss before income tax expense
-10,132
-10,035
-8,277*
-8,614
Income tax expense
7
7
10*
6
Net loss
-10,139
-10,042
-8,287*
-8,620
Unrealized loss (gain) on marketable securities
-11
-76
-40*
64
Comprehensive loss
-10,150
-10,118
-8,328
-8,556
Basic EPS
-0.19
-0.19
-0.172
-0.17
Basic Average Shares
53,894,295
53,793,490
48,354,593
49,630,119
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$10,150K
(-31.51%↓ Y/Y)
Net loss
-$10,139K
(-31.69%↓ Y/Y)
Unrealized loss (gain) on
marketable securities
-$11K
(42.11%↑ Y/Y)
Loss before income
tax expense
-$10,132K
(-31.70%↓ Y/Y)
Income tax expense
$7K
(16.67%↑ Y/Y)
Other income, net
$366K
(16.56%↑ Y/Y)
Operating loss
-$10,498K
(-31.11%↓ Y/Y)
Research and development
$8,153K
(40.04%↑ Y/Y)
General and
administrative
$2,345K
(7.32%↑ Y/Y)
Buy us a coffee
DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (DMAC)